Search research articles
Contact Us
Filters
Showing results (81-90 of 291) with videos related to
Page
of 30
Sort By:
Cardiovascular Drugs and Therapy
|
October 25, 2008
Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus
Nehal N Mehta, Matthew Sheetz, Karen Price, et al.
The Journal of Investigative Dermatology
|
January 15, 2016
Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Reveals a More Atherogenic Profile
Wynnis L Tom, Martin P Playford, Shehla Admani, et al.
Nature Communications
|
October 26, 2017
Hyperlipidemia-induced cholesterol crystal production by endothelial cells promotes atherogenesis
Yvonne Baumer, Sara McCurdy, Tina M Weatherby, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
November 1, 2017
Association of Tumor Necrosis Factor Inhibitor Treatment With Reduced Indices of Subclinical Atherosclerosis in Patients With Psoriatic Disease
Lihi Eder, Aditya A Joshi, Amit K Dey, et al.
Journal of the American Academy of Dermatology
|
February 19, 2017
Psoriasis and comorbid diseases: Implications for management
Junko Takeshita, Sungat Grewal, Sinéad M Langan, et al.
Journal of the American Heart Association
|
March 4, 2014
Endothelial cell-, platelet-, and monocyte/macrophage-derived microparticles are elevated in psoriasis beyond cardiometabolic risk factors
Junko Takeshita, Emile R Mohler, Parasuram Krishnamoorthy, et al.
The American Journal of Medicine
|
July 18, 2012
Vitamin D, metabolic dyslipidemia, and metabolic syndrome in rheumatoid arthritis
Joshua F Baker, Nehal N Mehta, Daniel G Baker, et al.
Current Cardiology Reports
|
February 16, 2022
Updates in the Impact of Chronic Systemic Inflammation on Vascular Inflammation by Positron Emission Tomography (PET)
Philip M Parel, Alexander R Berg, Christin G Hong, et al.
Journal of Drugs in Dermatology : JDD
|
August 27, 2020
The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)
M Alan Menter, Nehal N Mehta, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology
|
June 29, 2012
The impact of psoriasis on 10-year Framingham risk
Nehal N Mehta, Parasuram Krishnamoorthy, YiDing Yu, et al.
Page
of 30
Search research articles
Search
Showing results (81-90 of 291) with videos related to
Sort By:
Page
of 30
Cardiovascular Drugs and Therapy
|
October 25, 2008
Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus
Nehal N Mehta, Matthew Sheetz, Karen Price, et al.
The Journal of Investigative Dermatology
|
January 15, 2016
Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Reveals a More Atherogenic Profile
Wynnis L Tom, Martin P Playford, Shehla Admani, et al.
Nature Communications
|
October 26, 2017
Hyperlipidemia-induced cholesterol crystal production by endothelial cells promotes atherogenesis
Yvonne Baumer, Sara McCurdy, Tina M Weatherby, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
November 1, 2017
Association of Tumor Necrosis Factor Inhibitor Treatment With Reduced Indices of Subclinical Atherosclerosis in Patients With Psoriatic Disease
Lihi Eder, Aditya A Joshi, Amit K Dey, et al.
Journal of the American Academy of Dermatology
|
February 19, 2017
Psoriasis and comorbid diseases: Implications for management
Junko Takeshita, Sungat Grewal, Sinéad M Langan, et al.
Journal of the American Heart Association
|
March 4, 2014
Endothelial cell-, platelet-, and monocyte/macrophage-derived microparticles are elevated in psoriasis beyond cardiometabolic risk factors
Junko Takeshita, Emile R Mohler, Parasuram Krishnamoorthy, et al.
The American Journal of Medicine
|
July 18, 2012
Vitamin D, metabolic dyslipidemia, and metabolic syndrome in rheumatoid arthritis
Joshua F Baker, Nehal N Mehta, Daniel G Baker, et al.
Current Cardiology Reports
|
February 16, 2022
Updates in the Impact of Chronic Systemic Inflammation on Vascular Inflammation by Positron Emission Tomography (PET)
Philip M Parel, Alexander R Berg, Christin G Hong, et al.
Journal of Drugs in Dermatology : JDD
|
August 27, 2020
The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2)
M Alan Menter, Nehal N Mehta, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology
|
June 29, 2012
The impact of psoriasis on 10-year Framingham risk
Nehal N Mehta, Parasuram Krishnamoorthy, YiDing Yu, et al.
Page
of 30